Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sund, Fredrik [VerfasserIn]   i
 Tufveson, Gunnar [VerfasserIn]   i
 Döhler, Bernd [VerfasserIn]   i
 Opelz, Gerhard [VerfasserIn]   i
 Eriksson, Britt-Marie [VerfasserIn]   i
Titel:Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients
Titelzusatz:a 10-year experience
Verf.angabe:Fredrik Sund, Gunnar Tufveson, Bernd Döhler, Gerhard Opelz and Britt-Marie Eriksson
Jahr:2013
Umfang:8 S.
Fussnoten:Advance access publication 14 December 2012 ; Gesehen am 27.01.2022
Titel Quelle:Enthalten in: Nephrology, dialysis, transplantation
Ort Quelle:Oxford : Oxford Univ. Press, 1986
Jahr Quelle:2013
Band/Heft Quelle:28(2013), 3, Seite 758-765
ISSN Quelle:1460-2385
Abstract:Cytomegalovirus (CMV) remains an important pathogen in transplant patients, and valacyclovir (VACV) prophylaxis 8 g/day has been used in high-risk CMV-seromismatched [D+/R−] renal transplant patients to decrease CMV disease. Neurotoxic adverse effects have limited its use, and the aim of the present study was to retrospectively evaluate low-dose VACV prophylaxis, 3 g/day for 90 days after transplantation, in 102 D+/R− renal transplant patients.We compared patient and graft survival rates up to 5 years after transplantation with the data from the Collaborative Transplant Study Group (CTS) database. The incidence of CMV disease, rejection and neurotoxic adverse effects was analyzed up to 1 year after transplantation.The patient and graft survival rates up to 5 years were comparable with those derived from the CTS. CMV disease was diagnosed in 25% of the patients and 2% developed tissue-invasive CMV disease. The rejection frequency was 22% and neurotoxic adverse effects were seen in 2% of the patients.Low-dose VACV prophylaxis (3 g/day) for 90 days post-transplantation results in high patient and graft survival rates and reduces the incidence of CMV disease. Neurotoxic adverse effects are minimal. We believe that low-dose VACV prophylaxis should be considered to form one of the arms in future prospective comparison studies for the prevention of CMV disease in the high-risk D+/R− population of renal transplant patients.
DOI:doi:10.1093/ndt/gfs531
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1093/ndt/gfs531
 DOI: https://doi.org/10.1093/ndt/gfs531
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1787289613
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68871338   QR-Code
zum Seitenanfang